BioMarin Pharma (BMRN): Four Domain Field Data Stronger Than Previous Two Domain Data - Leerink

October 12, 2016 10:20 AM EDT
Get Alerts BMRN Hot Sheet
Price: $83.12 +0.81%

Rating Summary:
    19 Buy, 6 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 17 | Down: 27 | New: 28
Trade BMRN Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Leerink Partners analyst, Joseph Schwartz, reiterated his Outperform rating on share of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) after connecting with patient advocates and seeing additional clinical data including all four domains of the primary endpoint. The analyst believes that this appears stronger than the two-domain data presented previously.

The analyst stated "we are encouraged by growing awareness and improving diagnostic protocols for the disease, which could ultimately boost patient identification and long term Brineura sales. However, we noticed a lower propensity to treat patients in ex-US geographies". This led the analyst to temper his outlook for markets beyond the US borders.

No change to the price target of $127.

For an analyst ratings summary and ratings history on BioMarin Pharmaceutical Inc. click here. For more ratings news on BioMarin Pharmaceutical Inc. click here.

Shares of BioMarin Pharmaceutical Inc. closed at $91.67 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments

Add Your Comment